Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Matthew H TaylorCourtney B BettsLauren MaloneyEric NadlerAlain Patrick AlgaziMichael J GuarinoJohn J NemunaitisAntonio JimenoPriti PatelVeerendra MunugalavadlaLin TaoDouglas AdkinsJerome H GoldschmidtEzra E W CohenLisa M CoussensPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Despite lack of clinical efficacy, immune subset analyses suggest that there are additive effects of this combination; however, the associated toxicity limits the feasibility of combination treatment with pembrolizumab and acalabrutinib in patients with recurrent or metastatic HNSCC.